KREBSBEHANDLUNG

Patent europeic · EP2817011 · En vigur

Inscripziun en il register

Numer da publicaziun
EP2817011
Numer da la dumonda
EP13751188
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
21-02-2013
Publitgà
31-12-2014
Concedì
05-01-2022
La protecziun finescha il pli tard
20-02-2033
Proxima taxa annuala scadenta
28-02-2027
Classas IPC
A61K 31/664 (2006.01)
A61K 31/675 (2006.01)
A61K 31/7068 (2006.01)
A61P 35/00 (2006.01)
A61K 31/685 (2006.01)
Prioritad
US 201261601438 P 21.02.2012
US 201361756419 P 24.01.2013
Dumonda PCT
PCT/US2013/027091 21.02.2013
Publicaziun PCT
WO2013/126539 29.08.2013
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-03-2026

    Midada

    Published in Swissreg on 01.03.2026

  2. 01-03-2025

    Midada

    Published in Swissreg on 01.03.2025

  3. 01-03-2024

    Midada

    Published in Swissreg on 01.03.2024

  4. 06-03-2023

    Midada

    Published in Swissreg on 06.03.2023

  5. 16-11-2022

    Midada

    Published in Swissreg on 16.11.2022

  6. 05-01-2022

    Concedì

    Published in Swissreg on 05.01.2022

Partidas

Possessur

ImmunoGenesis, Inc.

909 Fannin, Suite 2000, Houston TX 77010, US

Inventur

KROLL, Stewart

Oakland, CA 94705, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.